
Ablynx looks to GSK for new chief commercial officer
pharmafile | November 21, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Ablynx, johan heylan
Belgium-based biopharma firm Ablynx has appointed Johan Heylen to be its chief commercial officer and assume responsibility for all commercial activities.
Heylen has more than 20 years of experience in global biopharma sales, marketing and business development at GlaxoSmithKline, Servier and Wyeth.
Most recently he was executive director of GSK’s cancer immunotherapeutics unit where he headed the global commercial teams, and was responsible for the development and implementation of products in this portfolio.
Welcoming Heylen to the team is Dr Edwin Moses, chief executive of Ablynx, who says: “Johan joins Ablynx as chief commercial officer at an important stage in our development as a biopharmaceutical company. His extensive commercial experience with some of the world’s leading companies will help Ablynx to maximise the potential of our pipeline as our programmes move through the clinic and towards the market.”
On his appointment Heylen adds: “I look forward to working with the first-class team to support the company as it moves to the next stage of development and begins to anticipate the commercialisation of the first Nanobody-based therapeutics.”
Related Content

Top Ten most popular articles on Pharmafile.com this week
As we approach the Easter weekend, we at Pharmafocus hope all of our readers have …

Ablynx’s vobarilizumab trial fails and sees two patient deaths in systemic lupus erythematosus
Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed …

Top Ten most popular articles on Pharmafile.com this week
It’s the first Friday of February, and it’s time for another recap of the top …






